RP-3 by Replimune for Head And Neck Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Head And Neck Cancer.

More hospitals are billing patients as online messages surge

Health systems drowning in messages from patients are grasping for new ways to manage the deluge — including charging for especially time-consuming responses. In recent

July 13, 2023

Breakthrough in hemophilia A treatment: Sobi’s ALTUVOCT receives EU marketing authorization

Sobi® today announced the European Commission has granted Marketing Authorization for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in hemophilia

June 22, 2024

How did exposure to news on COVID-19 through social platforms impact psychological health and behavior?

The relationship between news on the COVID-19 pandemic through social media, feelings of fear and anxiety, and behavior.

September 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.